Related Experiment Video
Updated: May 20, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes
Adriano A M Truffa1, Christopher B Granger, Kyle R White
1Duke Clinical Research Institute and the Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705, USA.
Objectives:
The aim of this study was to address the knowledge gap using the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial database. We also assessed the association between serious infections and 90-day death or death/myocardial infarction (MI).
Background:
Little is known about the incidence, location, etiological organisms, and outcomes of infection in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
Methods:
We analyzed data from 5,745 STEMI patients enrolled in the APEX-AMI trial. Detailed information on infection was collected for all patients. We described characteristics of patients according to infection and details of infection. Cox proportional hazards models were used to assess 90-day outcomes among patients with and without infections after adjusting for associated clinical variables and with infection as a time-dependent covariate.
Results:
Overall, 138 patients developed a serious infection (2.4%), most of whom presented with a single-site infection. The median (25th, 75th percentile) time until diagnosis of infection was 3 (1, 6) days. The most commonly identified organism was Staphylococcus aureus, and the main location of infection was the bloodstream. These patients had more comorbidities and lower procedural success at index percutaneous coronary intervention than those without infections. Serious infection was associated with significantly higher rates of 90-day death (adjusted hazard ratio: 5.6; 95% confidence interval: 3.8 to 8.4) and death or MI (adjusted hazard ratio: 4.9; 95% confidence interval: 3.4 to 7.1).
Conclusions:
Infections complicating the course of patients with STEMI were uncommon but associated with markedly worse 90-day clinical outcomes. Mechanisms for early identification of these high-risk patients as well as design of strategies to reduce their risk of infection are warranted.
Insights
Serious infections in ST-segment elevation myocardial infarction (STEMI) patients are uncommon but significantly increase the risk of death or death/myocardial infarction within 90 days. Early identification and infection prevention strategies are crucial.
Area of Science:
- Cardiology
- Infectious Diseases
- Clinical Research
Background:
- Limited understanding of infection characteristics and outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention.
- Need for data on infection incidence, causes, and impact on patient prognosis post-STEMI treatment.
Purpose of the Study:
- To investigate the incidence, characteristics, and clinical outcomes of serious infections in STEMI patients from the APEX-AMI trial.
- To assess the association between serious infections and 90-day mortality or the composite endpoint of death/myocardial infarction.
Main Methods:
- Analysis of 5,745 STEMI patients from the APEX-AMI trial database.
- Detailed collection and description of infection data, including organism and location.
- Cox proportional hazards models used to evaluate 90-day outcomes, adjusting for clinical variables and treating infection as a time-dependent covariate.
Main Results:
- Serious infections occurred in 2.4% of patients, primarily bloodstream infections caused by Staphylococcus aureus.
- Patients with infections had more comorbidities and lower procedural success rates.
- Serious infection was significantly associated with increased 90-day mortality (aHR 5.6) and death/MI (aHR 4.9).
Conclusions:
- Infections are infrequent but severely impact 90-day outcomes in STEMI patients.
- Highlights the need for early identification of high-risk patients and development of infection-reducing strategies.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis II: Clinical Features and Diagnostic Tests
Endocarditis I: Introduction
Myocarditis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Endocarditis III: Medical Management
